Format

Send to

Choose Destination
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):34-8.

Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.

Author information

1
UMDNJ-New Jersey Medical School, Newark, NJ, USA. robert.wallis@columbia.ppdi.com

Abstract

Several studies show that the risk of granulomatous infections following therapy with the anti-tumor necrosis factor (TNF) antibody infliximab is higher than after treatment with the soluble TNFRp75 immunoglobulin fusion construct etanercept. Therefore, despite sharing a common target, it is possible that the actual mode of action of the 2 biologicals differs in vivo. TNF is known to participate in the induction and maintenance of protective granulomas at multiple steps, and evidence supporting a differential inhibition of TNF bioactivity and signaling by the 2 drugs is discussed.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center